The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
MCPH1 (BRIT1) and outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) harboring EGFR mutations.
M. Rosario Garcia-Campelo
No relevant relationships to disclose
Miquel Taron
No relevant relationships to disclose
Susana Benlloch
No relevant relationships to disclose
Jose Javier Sanchez
No relevant relationships to disclose
Carlota Costa
No relevant relationships to disclose
Ana Gimenez Capitan
No relevant relationships to disclose
Jordi Bertran-Alamillo
No relevant relationships to disclose
Clara Mayo
No relevant relationships to disclose
Miguel Angel Molina-Vila
No relevant relationships to disclose
Margarita Majem
No relevant relationships to disclose
Teresa Moran
No relevant relationships to disclose
Bartomeu Massuti
No relevant relationships to disclose
Carlos Camps
No relevant relationships to disclose
Dolores Isla
No relevant relationships to disclose
Manuel Cobo
No relevant relationships to disclose
Sara Cros
No relevant relationships to disclose
Laia Capdevila
No relevant relationships to disclose
Enric Carcereny Costa
No relevant relationships to disclose
Santiago Viteri Ramirez
No relevant relationships to disclose
Rafael Rosell
No relevant relationships to disclose